CompletedNCT02493777
Official study titlePh 3 Multicenter OL Treatment-optimized RDBPC Forced-withdrawal, Parallel Grp Study to Evaluate Safety & Efficacy of Evening Dosed HLD200, a Novel DR/ER Formulation (DELEXIS) of MPH HCl in Children Aged 6-12 With ADHD in Classroom Setting
This study has finished and is no longer accepting participants.
Multiple locations, including Newport BeachADHDMedication studyAges 6–12
- Countries
- United States
- Sponsor
- Ironshore Pharmaceuticals and Development, Inc
CompletedNCT02520388
Official study titlePh 3 Multicenter DBRCT Parallel Group Study to Evaluate Safety & Efficacy of Evening-dosed HLD200, a Novel Delayed & Extended Release Formulation (DELEXIS) of MPH HCl, on Post-waking, Early Morning Function in Children Aged 6-12 With ADHD
This study has finished and is no longer accepting participants.
Multiple locations, including Newport BeachADHDMedication studyAges 6–12
- Countries
- United States
- Sponsor
- Ironshore Pharmaceuticals and Development, Inc
CompletedNCT00885807
Official study titlePsychometric Validation of the Weiss Functional Impairment Rating Scale and the Weiss Symptom Record in Patients With Attention-Deficit Hyperactivity Disorder
This study has finished and is no longer accepting participants.
In VancouverADHDObservational studyAges 7+
- Countries
- Canada
- Sponsor
- University of British Columbia
CompletedNCT00566449
What is this study about?Researchers compared JNJ-31001074 and placebo, tracking side effects to assess safety in adults with ADHD.
This study has finished and is no longer accepting participants.
Multiple locations, including IrvineADHDMedication studyAges 18–64
- Countries
- United States
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT00471354
Official study titleEvaluation of Academic Performance in Asian Children Aged 8 to 11 Years With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine Hydrochloride
This study has finished and is no longer accepting participants.
Multiple locations, including BeijingADHDMedication studyAges 8–11
- Countries
- China, South Korea, Taiwan
- Sponsor
- Eli Lilly and Company
CompletedNCT02884544
What is this study about?Researchers studied HLD100, tracking side effects to assess safety and tolerability in children with ADHD.
This study has finished and is no longer accepting participants.
In Las VegasADHDMedication studyAges 6–12
- Countries
- United States
- Sponsor
- Ironshore Pharmaceuticals and Development, Inc
TerminatedNCT00965419
What is this study about?Researchers are studying Edivoxetine, tracking side effects to assess long-term safety and tolerability in children with ADHD.
This study ended early.
Multiple locations, including Spring ValleyADHDMedication studyAges 6–18
- Countries
- United States, Canada, Taiwan
- Sponsor
- Eli Lilly and Company
CompletedNCT00518232
Official study titleThe Effective and Tolerable Titration Scheme and Dosage in Children With Attention-deficit Hyperactivity Disorder Treated With OROS-Methylphenidate
This study has finished and is no longer accepting participants.
Location not clearly listedADHDMedication studyAges 6–19
- Countries
- Sponsor
- Johnson & Johnson Taiwan Ltd
CompletedNCT00714688
Official study titleA Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS Methylphenidate (54 and 72 mg/Day) in Adults With Attention Deficit/Hyperactivity Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including AntwerpADHDMedication studyAges 18–65
- Countries
- France, United Kingdom, Switzerland, + 8 others
- Sponsor
- Janssen-Cilag International NV
CompletedNCT04943796
Official study titlePrevalence of ADHD and Health Outcomes in Adult Outpatients With Psychiatric Disorders: a Multi-country, Two-part, Observational Study
This study has finished and is no longer accepting participants.
Multiple locations, including BurnabyADHDObservational studyAges 18+
- Countries
- Canada, United Kingdom, Switzerland, + 3 others
- Sponsor
- Takeda
CompletedNCT05257265
What is this study about?Researchers compared Centanafadine Hydrochloride and placebo to find out how the approaches affected ADHD symptoms in young people with ADHD.
This study has finished and is no longer accepting participants.
In New YorkADHDMedication studyAges 13–17
- Countries
- United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
UnknownNCT03666416
Current recruitment status is unconfirmed.
In LaramieADHDBehavioural studyAges 18–29
- Countries
- United States
- Sponsor
- University of Wyoming
